A Clinical Study to Evaluate the Efficacy and SPF of Two Test Materials According to an Adaptation of the Guidelines of the FDA Sunscreen Drug Products for Over-the-Counter Human Use

NCT07789639 | Recruiting Phase 4 FDA Drug

• 1 other identifier: ECRLNC2026-0016 PB
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Approximately 70 subjects (35 subjects per light and dark group) will be enrolled in this clinical study (to complete with a minimum of 10 subjects per skin type (I-VI) to assess the effects of known UV Radiation dosage on light and dark skin, assess the protective effect of two SPF test materials, placebo product, and standard sunscreen ('Pad O') on skin, before and after a known UV Radiation dosage and collect the interstitial dermal fluid from approximately 60 subjects and send to Eurofins Discovery for analysis. The following study evaluations will be obtained: SPF Determination, Visual Assessment of Erythema, Chromameter and Mexameter measurements, Digital photography, Thermometer readings and Collection of Dermal Interstitial Fluid (IDF).

Conditions

Epidermis; Ultraviolet Exposure

Keywords

SPF; Ultraviolet Radiation; Erythema

Outcome Measures

Primary Outcomes (5)

• Chromameter

  This study will use a reflectance colorimeter, CM-700d (Konica Minolta) or equivalent, a handheld device that measures skin color in the L\*a\*b\* color space. The L\*, a\*, and b\* values will be measured from at least 3 different locations on the subject's back and then used to calculate the ITA°, which can be used to estimate a subject's MEDu

  Chromameter measurements will be obtained at Day 1 Baseline and Day 3 post treatment

• Dermal Darkening Evaluation

  A technician will determine post UV dose immediate responses using the assessment scale listed below: Table 4. Immediate Response Codes N No Immediate response D Immediate Darkening R Immediate Reddening H Immediate Generalized Heat Response Spreading Beyond the Subsite

  Baseline and Day 3 Post-treatment

• Erythema Dermal Evaluation

  Table 5. Grading Scale for Erythema Responses to UV Doses Administered to Untreated Sites and Sunscreen-Treated Sites 0 = No erythema response or inconclusive response 0.5 = Ambiguous erythema and/or no clear border and/or not filling more than 50% of the exposure subsite. (Minimally perceptible erythema) 1. = Perceptible unambiguous erythema with clearly defined borders (filling more than 50% of the exposure subsite) 2. = Moderate to intense erythema

  Baseline and Day 3 Post-treatment

• Mexameter

  Three Mexameter measurements will be obtained from the subjects randomized test sites on the back at each designated time point to assess erythema and melanin.

  Baseline and Day 3 Post-treatment

• Dermal interstitial fluid

  Client-provided human interstitial fluid samples and commercially-sourced artificial interstitial fluid will be evaluated at multiple dilutions for levels of IL-1α, IL-6, IL-8, and VEGF-A using Luminex methodology (Thermo Fisher ProcartaPlex catalog #PPXT-04). Two (2) client-provided human interstitial fluid samples will be evaluated at 8 dilutions in singlicate.

  At the Baseline timepoint, a sub-site to the top left of the testing area will be used for the micro-needling.

Secondary Outcomes (1)

• Thermometer reading

  Right before and immediately after UV Exposure.

Study Arms (3)

No SPF Placebo

PLACEBO COMPARATOR

Other: No sunscreen

Test Product

EXPERIMENTAL

Drug: Hybrid sunscreen

Benchmark

ACTIVE COMPARATOR

Drug: Chemical sunscreen

Interventions

Hybrid sunscreen DRUG

Hybrid D II SPF 30

Test Product

Chemical sunscreen DRUG

Chemical SPF 30

Benchmark

No sunscreen OTHER

No SPF Placebo

No SPF Placebo

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject is male or female between 18 - 75 years old, providing legally effective, written informed consent in conformance with 45 CFR Parts 160 and 164
• Subject has a Fitzpatrick Skin Type of I, II, or III, Light Skin Group or IV, V, or VI Dark Skin Group with an approximately equal distribution of all skin types (approximately 10 of each Fitzpatrick skin type) within each group as determined by ITA Angle
• Subject agrees to undergo the micro needling procedure on their back (a total of 5 sites)
• Subject should not have their back shaved or waxed 3 days prior to the start of the study
• Subject is able to read, write, speak, and understand English
• Subject is in good general health
• Subject agrees to avoid UV exposure to the test area for the duration of the study
• Subject is willing to wear loose-fitting clothing that exposes mid to lower back for study visits
• Subject is dependable and able to follow directions as outlined in the protocol and anticipates being available for all study visits
• Subject is willing to participate in all study evaluations and follow all instructions
• Subject has a current Subject Profile Form on file at ECRL
• Subject has uniform skin color over the test area; ITA° calculation range ≤10-point difference (example: 35.6°-45.6°)
• Subject agrees to sign a Photography Release Form, providing consent for the capture of digital images for use in relation to this clinical study
• Subject has completed a HIPAA Authorization Form in conformance with 45 CFR Parts 160 and 164

You may not qualify if:

• Female subject is pregnant, nursing, planning a pregnancy, or using inadequate birth control
• Subject has a history of abnormal response to sunlight/UV radiation; sensitivity to any ingredient of the test materials, standard or latex; or any known allergies to sunscreen, cosmetic, and/or toiletry products
• Subject has a history of or any current significant dermatological condition, such as atopic dermatitis (eczema), psoriasis, skin cancer, melanoma, active dermal lesions, nevi, keloids blemishes, abnormal scarring or moles, lupus, diabetes, or connective tissue disease that would increase the risk associated with participation
• Subject has received treatment with sympathomimetics, antihistamines, vasoconstrictors, non-steroidal anti-inflammatory agents, and/or systemic or topical corticosteroids within one week prior to initiation of the study.
• Subject has used a prohibited medication (per separately provided prohibited medication list) within the specified timeframes prior to initiation of the study
• Subject has used/applied any personal care products (e.g. lotions, sunscreens, sunless tanners) and/or topical medications in/on the testing area (the back between the shoulder blades and the waist line) within 24 hours prior to Day 1 or during the study
• Subject has any known communicable disease(s) (e.g. HIV, STD's, Hepatitis B, Hepatitis C, etc.)
• Subject has any skeletal protrusions and/or extreme areas of curvature in the test area
• Subject with medical treatment/vaccination planned during the study, which would make the subject ineligible, place the subject at undue risk, or confound the outcome of the study, per the discretion of the PI.
• Subject has undergone any surgical procedure in the last 12 months
• Subject has undergone chemical or physical treatment procedures in the test area within the last 12 months
• Subject is planning hospitalization during the study
• Subject exceeds the weight limit of 300 pounds due to equipment limitations
• Subject has any condition that might confound the study results, increase the risk associated with participation, or interfere with study participation;
• Subject has any visible sunburn or suntan in testing area

Sponsors & Collaborators

• Good Molecules, LLC: lead
• Eurofins CRL Cosmetics, Inc.: collaborator

Study Sites (1)

Eurofins | CRL, Cosmetics LLC

Winston-Salem, North Carolina, 27101, United States

RECRUITING

MeSH Terms

Conditions

Erythema

Condition Hierarchy (Ancestors)

Skin Diseases; Skin and Connective Tissue Diseases; Skin Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Alexis Chantal, PA-C

CONTACT

(336) 725-6501; Alexis.Chantal@cpt.eurofinsus.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 14, 2026
• First Posted: August 27, 2026
• Study Start (Estimated): September 14, 2026
• Primary Completion (Estimated): February 24, 2027
• Study Completion (Estimated): April 7, 2027
• Last Updated: August 27, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)